P. Pollard, J. Bri-re-È, N. Alam, J. Barwell, E. Barclay et al., Accumulation of Krebs cycle intermediates and over-expression of HIF1?? in tumours which result from germline FH and SDH mutations, Human Molecular Genetics, vol.14, issue.15, pp.2231-2239, 2005.
DOI : 10.1093/hmg/ddi227

O. Yogev, O. Yogev, E. Singer, E. Shaulian, M. Goldberg et al., Fumarase: A Mitochondrial Metabolic Enzyme and a Cytosolic/Nuclear Component of the DNA Damage Response, PLoS Biology, vol.452, issue.3, p.1000328, 2010.
DOI : 10.1371/journal.pbio.1000328.s003

G. Hudes, Targeting mTOR in renal cell carcinoma, Cancer, vol.22, issue.18S, pp.2313-2320, 2009.
DOI : 10.1002/cncr.24239

R. Motzer, B. Escudier, S. Oudard, T. Hutson, C. Porta et al., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-456, 2008.
DOI : 10.1016/S0140-6736(08)61039-9

R. Motzer, G. Hudes, B. Curti, D. Mcdermott, B. Escudier et al., Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.25, issue.25, pp.3958-3964, 2007.
DOI : 10.1200/JCO.2006.10.5916

G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin et al., Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.22, 2007.
DOI : 10.1056/NEJMoa066838

A. Pantuck, D. Seligson, T. Klatte, H. Yu, J. Leppert et al., Prognostic relevance of the mTOR pathway in renal cell carcinoma, Cancer, vol.9, issue.11, pp.2257-2267, 2007.
DOI : 10.1002/cncr.22677

D. Cho, S. Signoretti, S. Dabora, M. Regan, A. Seeley et al., Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma, Clinical Genitourinary Cancer, vol.5, issue.6, pp.379-385, 2007.
DOI : 10.3816/CGC.2007.n.020

R. Figlin, P. De-souza, D. Mcdermott, J. Dutcher, A. Berkenblit et al., Analysis of PTEN and HIF-1?? and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-??, Cancer, vol.7, issue.16, pp.3651-3660, 2009.
DOI : 10.1002/cncr.24438

A. Toschi, E. Lee, N. Gadir, M. Ohh, and D. Foster, Differential Dependence of Hypoxia-inducible Factors 1?? and 2?? on mTORC1 and mTORC2, Journal of Biological Chemistry, vol.283, issue.50, pp.34495-34499, 2008.
DOI : 10.1074/jbc.C800170200

J. Chen, K. Futami, D. Petillo, J. Peng, P. Wang et al., Deficiency of FLCN in Mouse Kidney Led to Development of Polycystic Kidneys and Renal Neoplasia, PLoS ONE, vol.4, issue.10, p.3581, 2008.
DOI : 10.1371/journal.pone.0003581.s003

T. Hartman, E. Nicolas, A. Klein-szanto, T. Saleem, T. Cash et al., The role of the Birt-Hogg-Dub protein in mTOR activation and renal tumorigenesis é

Y. Hasumi, M. Baba, R. Ajima, H. Hasumi, V. Valera et al., Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2, Proceedings of the National Academy of Sciences, vol.106, issue.44, pp.18722-18727, 2009.
DOI : 10.1073/pnas.0908853106

V. Hudon, S. Sabourin, A. Dydensborg, V. Kottis, A. Ghazi et al., Renal tumour suppressor function of the Birt-Hogg-Dub syndrome gene product folliculin é, J

S. Yamaguchi, S. Yoshihiro, H. Matsuyama, K. Nagao, K. Fukunaga et al., The allelic loss of chromosome 3p25 with c-myc gain is related to the development of clear-cell renal cell carcinoma, Clinical Genetics, vol.18, issue.3, pp.184-191, 2003.
DOI : 10.1034/j.1399-0004.2003.00035.x

J. Gordan, P. Lal, V. Dondeti, R. Letrero, K. Parekh et al., HIF-?? Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma, Cancer Cell, vol.14, issue.6, pp.435-446, 2008.
DOI : 10.1016/j.ccr.2008.10.016

K. Furge, J. Chen, J. Koeman, P. Swiatek, K. Dykema et al., Detection of DNA Copy Number Changes and Oncogenic Signaling Abnormalities from Gene Expression Data Reveals MYC Activation in High-Grade Papillary Renal Cell Carcinoma, Cancer Research, vol.67, issue.7, pp.3171-3176, 2007.
DOI : 10.1158/0008-5472.CAN-06-4571

L. Schmidt, M. Nickerson, D. Angeloni, G. Glenn, M. Walther et al., EARLY ONSET HEREDITARY PAPILLARY RENAL CARCINOMA: GERMLINE MISSENSE MUTATIONS IN THE TYROSINE KINASE DOMAIN OF THE MET PROTO-ONCOGENE, The Journal of Urology, vol.172, issue.4, pp.1256-1261, 2004.
DOI : 10.1097/01.ju.0000139583.63354.e0

T. Klatte, A. Pantuck, J. Said, D. Seligson, N. Rao et al., Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma, Clinical Cancer Research, vol.15, issue.4
DOI : 10.1158/1078-0432.CCR-08-1229

S. Bellon, P. Kaplan-lefko, Y. Yang, Y. Zhang, J. Moriguchi et al., c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations, Journal of Biological Chemistry, vol.283, issue.5, pp.2675-2683, 2008.
DOI : 10.1074/jbc.M705774200

D. Goldschneider and P. Mehlen, Dependence receptors: a new paradigm in cell signaling and cancer therapy, Oncogene, vol.17, issue.13, pp.1865-1882, 2010.
DOI : 10.1016/S0959-8049(97)00309-2

URL : https://hal.archives-ouvertes.fr/hal-00474454

A. Bommi-reddy, I. Almeciga, J. Sawyer, C. Geisen, W. Li et al., Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen, Proceedings of the National Academy of Sciences, vol.105, issue.43, pp.16484-16489, 2008.
DOI : 10.1073/pnas.0806574105

B. Costa, D. Dettori, A. Lorenzato, C. Bardella, N. Coltella et al., Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis, The FASEB Journal, vol.24, issue.8, pp.9-146928, 1096.
DOI : 10.1096/fj.09-146928

R. Fisher, S. Rosenberg, and G. Fyfe, Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma, Cancer J Sci Am, vol.6, pp.55-57, 2000.

D. Mcdermott, M. Regan, J. Clark, L. Flaherty, G. Weiss et al., Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.23, issue.1, pp.133-141, 2005.
DOI : 10.1200/JCO.2005.03.206

M. Atkins, M. Regan, D. Mcdermott, J. Mier, E. Stanbridge et al., Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer, Clinical Cancer Research, vol.11, issue.10
DOI : 10.1158/1078-0432.CCR-04-2019

J. Jones, H. Otu, F. Grall, D. Spentzos, H. Can et al., Proteomic Identification of Interleukin-2 Therapy Response in Metastatic Renal Cell Cancer, The Journal of Urology, vol.179, issue.2, pp.730-736, 2008.
DOI : 10.1016/j.juro.2007.09.016

R. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam et al., Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.17, issue.8, pp.2530-2540, 1999.
DOI : 10.1200/JCO.1999.17.8.2530

T. Mekhail, R. Abou-jawde, G. Boumerhi, S. Malhi, L. Wood et al., Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.23, issue.4, pp.832-841, 2005.
DOI : 10.1200/JCO.2005.05.179